COVID-19 vaccines should be evaluated from the societal perspective

References

• Institute for Health Metrics and Evaluation. COVID-19 Projections [Internet]. Institute for Health Metrics and Evaluation. 2023 [cited 2023 Mar 15]. Available from: https://covid19.healthdata.org/.
   Google Scholar
• Prabhu M, Gergen J. History’s seven deadliest plagues [Internet]. Gavi, the Vaccine Alliance. 2021 [cited 2023 Mar 15]. Available from: https://www.gavi.org/vaccineswork/historys-seven-deadliest-plagues.
   Google Scholar
• Huang G, Guo F, Zimmermann KF, et al. The effect of the COVID-19 pandemic on life expectancy in 27 countries. Sci Rep. 2023;13(1):8911. doi: 10.1038/s41598-023-35592-9.
   PubMed Web of Science ®Google Scholar
• Sachs JD, Karim SSA, Aknin L, et al. The Lancet Commission on lessons for the future from the COVID-19 pandemic. Lancet. 2022;400(10359):1224–1280. doi: 10.1016/S0140-6736(22)01585-9.
   PubMed Web of Science ®Google Scholar
• The World Bank. WDR 2022 Chapter 1. Introduction [Internet]. World Bank. 2022 [cited 2023 Mar 15]. Available from: https://www.worldbank.org/en/publication/wdr2022/brief/chapter-1-introduction-the-economic-impacts-of-the-covid-19-crisis.
   Google Scholar
• International Monetary Fund. Fiscal Monitor Update, January 2021 [Internet]. International Monetary Fund. 2021 [cited 2023 Mar 15]. Available from: https://www.imf.org/en/Publications/FM/Issues/2021/01/20/fiscal-monitor-update-january-2021.
   Google Scholar
• Bonotti M, Zech ST. The human, economic, social, and political costs of COVID-19. Recovering Civil Dur COVID-19. 2021;1–36. doi: 10.1007/978-981-33-6706-7_1.
   Google Scholar
• Jarvis CI, Gimma A, van Zandvoort K, et al. The impact of local and national restrictions in response to COVID-19 on social contacts in England: a longitudinal natural experiment. BMC Med. 2021;19(1):52. doi: 10.1186/s12916-021-01924-7.
   PubMed Web of Science ®Google Scholar
• Repucci S, Slipowitz A. Democracy under Lockdown [Internet]. Freedom House; 2020 [cited 2022 Aug 25]. Available from: https://freedomhouse.org/report/special-report/2020/democracy-under-lockdown.
   Google Scholar
• Lekagul A, Chattong A, Rueangsom P, et al. Multi-dimensional impacts of coronavirus disease 2019 pandemic on sustainable development goal achievement. Global Health. 2022;18(1):65. doi: 10.1186/s12992-022-00861-1.
   PubMed Web of Science ®Google Scholar
• Newman E. Covid-19: a human security analysis. Global Society. 2022;36(4):431–454. doi: 10.1080/13600826.2021.2010034.
   Web of Science ®Google Scholar
• Organisation for Economic Co-operation and Development. Enhancing public trust in COVID-19 vaccination: the role of governments [Internet]. 2021 [cited 2023 Mar 15]. Available from: https://www.oecd.org/coronavirus/policy-responses/enhancing-public-trust-in-covid-19-vaccination-the-role-of-governments-eae0ec5a/.
   Google Scholar
• The White House. National COVID-19 preparedness plan [Internet]. The White House. 2022 [cited 2023 Mar 15]. Available from: https://www.whitehouse.gov/covidplan/.
   Google Scholar
• Lazarus JV, Romero D, Kopka CJ, et al. A multinational Delphi consensus to end the COVID-19 public health threat. Nature. 2022;611(7935):332–345. doi: 10.1038/s41586-022-05398-2.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Safety of COVID-19 vaccines [Internet]. Centers for Disease Control and Prevention. 2023 [cited 2023 Mar 15]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/safety-of-vaccines.html.
   Google Scholar
• U.S. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes Moderna, Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster Dose [Internet]. FDA. FDA; 2022 [cited 2023 Mar 15]. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-moderna-pfizer-biontech-bivalent-covid-19-vaccines-use.
   Google Scholar
• Di Fusco M, Marczell K, Deger KA, et al. Public health impact of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in the first year of rollout in the United States. J Med Econ. 2022;25(1):605–617. doi: 10.1080/13696998.2022.2071427.
   PubMed Web of Science ®Google Scholar
• Watson OJ, Barnsley G, Toor J, et al. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis. 2022;22(9):1293–1302. doi: 10.1016/S1473-3099(22)00320-6.
   PubMed Web of Science ®Google Scholar
• Moghadas SM, Vilches TN, Zhang K, et al. The impact of vaccination on coronavirus disease 2019 (COVID-19) outbreaks in the United States. Clin Infect Dis. 2021;73(12):2257–2264. doi: 10.1093/cid/ciab079.
   PubMed Web of Science ®Google Scholar
• Tenforde MW. Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19–associated emergency department or urgent care encounters and hospitalizations among immunocompetent adults—VISION network, Nine States, September–November 2022. MMWR Morb Mortal Wkly Rep [Internet]. 2022 [cited 2023 Mar 15]; 71. Available from: https://www.cdc.gov/mmwr/volumes/71/wr/mm715152e1.htm.
   Google Scholar
• Chuenkitmongkol S, Solante R, Burhan E, et al. Expert review on global real-world vaccine effectiveness against SARS-CoV-2. Expert Rev Vaccines. 2022;21(9):1255–1268. doi: 10.1080/14760584.2022.2092472.
   PubMed Web of Science ®Google Scholar
• Bell E, Brassel S, Oliver E, et al. Estimates of the global burden of COVID-19 and the value of broad and equitable access to COVID-19 vaccines. Vaccines (Basel). 2022;10(8):1320. doi: 10.3390/vaccines10081320.
   PubMed Web of Science ®Google Scholar
• Kirson N, Swallow E, Lu J, et al. The societal economic value of COVID-19 vaccines in the United States. J Med Econ. 2022;25(1):119–128. doi: 10.1080/13696998.2022.2026118.
   PubMed Web of Science ®Google Scholar
• Appleby J. The public finance cost of covid-19. BMJ. 2022;376:o490. doi: 10.1136/bmj.o490.
   PubMedGoogle Scholar
• Deb P, Furceri D, Jimenez D, et al. The effects of COVID-19 vaccines on economic activity. Swiss J Econ Stat. 2022;158(1):3. doi: 10.1186/s41937-021-00082-0.
   PubMedGoogle Scholar
• Acharya VV, Johnson T, Sundaresan S, et al. The value of a cure: an asset pricing perspective. Natl Bur Econ Res. 2020. Available from https://www.nber.org/system/files/working_papers/w28127/revisions/w28127.rev0.pdf.
   Google Scholar
• Sandmann FG, Davies NG, Vassall A, et al. The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation. Lancet Infect Dis. 2021;21(7):962–974. doi: 10.1016/S1473-3099(21)00079-7.
   PubMed Web of Science ®Google Scholar
• Nealon J, Cowling BJ. Omicron severity: milder but not mild. Lancet. 2022;399(10323):412–413. doi: 10.1016/S0140-6736(22)00056-3.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Trends in disease severity and health care utilization during the early omicron variant period compared with previous SARS-CoV-2 high transmission periods—United States, December 2020–January 2022 | MMWR [Internet]. Centers for Disease Control and Prevention. 2022 [cited 2023 Sep 20]. Available from: https://www.cdc.gov/mmwr/volumes/71/wr/mm7104e4.htm.
   Google Scholar
• World Health Organization. Weekly epidemiological update on COVID-19 - 15 June 2023 [Internet]. 2023 [cited 2023 Jun 28]. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19.
   Google Scholar
• World Health Organization. Statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic [Internet]. 2023 [cited 2023 Jun 28]. Available from: https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic.
   Google Scholar
• Baker A, Chaudhuri E, Kremer M. Accelerating vaccinations [Internet]. International Monetary Fund. 2021 [cited 2023 Jun 28]. Available from: https://www.imf.org/en/Publications/fandd/issues/2021/12/Accelerating-Vaccinations-Baker-Chaudhuri-Kremer.
   Google Scholar
• Athey S, Conti RM, Fiedler M, et al. The economic case for federal investment in COVID-19 vaccines and therapeutics remains strong [Internet]. Brookings. 2022 [cited 2023 Jun 28]. Available from: https://www.brookings.edu/articles/the-economic-case-for-federal-investment-in-covid-19-vaccines-and-therapeutics-remains-strong/.
   Google Scholar
• Odihi D, Watts E, Patenaude B, et al. Economics of COVID-19 vaccines [Internet]. Johns Hopkins Coronavirus Resource Center. 2020 [cited 2023 Jun 28]. Available from: https://coronavirus.jhu.edu/vaccines/report/economics-of-covid-19-vaccines.
   Google Scholar
• World Bank. GDP per capita (current US$) [Internet]. World Bank Open Data. 2023 [cited 2023 Sep 19]. Available from: https://data.worldbank.org/indicator/NY.GDP.PCAP.CD.
   Google Scholar
• World Bank. GDP (current US$) - United States [Internet]. World Bank Open Data. 2023 [cited 2023 Nov 8]. Available from: https://data.worldbank.org/indicator/NY.GDP.MKTP.CD?end=2019&locations=US&start=1960.
   Google Scholar
• Our World in Data. Total COVID-19 vaccine doses administered [Internet]. 2023 [cited 2023 Sep 19]. Available from: https://ourworldindata.org/grapher/cumulative-covid-vaccinations.
   Google Scholar
• Kates J, Cox C, Michaud J. How much could COVID-19 vaccines cost the U.S. after commercialization? [Internet]. 2023 [cited 2023 Aug 10]. Available from: https://www.kff.org/coronavirus-covid-19/issue-brief/how-much-could-covid-19-vaccines-cost-the-u-s-after-commercialization/.
   Google Scholar
• Lazarus JV, Karim SSA, van Selm L, et al. COVID-19 vaccine wastage in the midst of vaccine inequity: causes, types and practical steps. BMJ Glob Health. 2022;7(4):e009010. doi: 10.1136/bmjgh-2022-009010.
   PubMed Web of Science ®Google Scholar
• Agrawal V, Sood N, Whaley CM. The impact of the global COVID-19 vaccination campaign on all-cause mortality. national bureau of economic research working paper series [Internet]. 2023;No. 31812. Available from: http://www.nber.org/papers/w31812.
   Google Scholar
• World Bank. Population, total [Internet]. World Bank Open Data. 2023 [cited 2023 Nov 8]. Available from: https://data.worldbank.org/indicator/SP.POP.TOTL.
   Google Scholar
• World Health Organization. WHO Coronavirus (COVID-19) Dashboard [Internet]. Available from: https://covid19.who.int/table.
   Google Scholar
• World Health Organization. From emergency response to long-term COVID-19 disease management: sustaining gains made during the COVID-19 pandemic [Internet]. 2023 [cited 2023 Jun 28]. Report No.: WHO/WHE/SPP/2023.1. Available from: https://www.who.int/publications-detail-redirect/WHO-WHE-SPP-2023.1.
   Google Scholar
• Abulsoud AI, El-Husseiny HM, El-Husseiny AA, et al. Mutations in SARS-CoV-2: insights on structure, variants, vaccines, and biomedical interventions. Biomed Pharmacother. 2023;157:113977. doi: 10.1016/j.biopha.2022.113977.
   PubMed Web of Science ®Google Scholar
• Dietler D, Kahn F, Inghammar M, et al. Waning protection after vaccination and prior infection against COVID-19-related mortality over 18 months. Clin Microbiol Infect. 2023;29(12):1573–1580. doi: 10.1016/j.cmi.2023.08.007.
   PubMedGoogle Scholar
• Sparrer MN, Hodges NF, Sherman T, et al. Role of spillover and spillback in SARS-CoV-2 transmission and the importance of one health in understanding the dynamics of the COVID-19 pandemic. J Clin Microbiol. 2023;61(7):e01610-22. doi: 10.1128/jcm.01610-22.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Updated COVID-19 vaccine recommendations are now available [Internet]. Centers for Disease Control and Prevention. 2023 [cited 2023 Sep 24]. Available from: https://www.cdc.gov/respiratory-viruses/whats-new/covid-vaccine-recommendations-9-12-2023.html.
   Google Scholar
• Are EB, Song Y, Stockdale JE, et al. COVID-19 endgame: from pandemic to endemic? Vaccination, reopening and evolution in low- and high-vaccinated populations. J Theor Biol. 2023;559:111368. doi: 10.1016/j.jtbi.2022.111368.
   PubMed Web of Science ®Google Scholar
• Kofman A, Kantor R, Adashi EY. Potential COVID-19 endgame scenarios: eradication, elimination, cohabitation, or conflagration? JAMA. 2021;326(4):303–304. doi: 10.1001/jama.2021.11042.
   PubMed Web of Science ®Google Scholar
• Oliu-Barton M, Pradelski BSR, Algan Y, et al. Elimination versus mitigation of SARS-CoV-2 in the presence of effective vaccines. Lancet Glob Health. 2022;10(1):e142–e147. doi: 10.1016/S2214-109X(21)00494-0.
   PubMed Web of Science ®Google Scholar
• Rahmandad H, Sterman J. Quantifying the COVID-19 endgame: is a new normal within reach? Syst Dyn Rev. 2022;38(4):329–353. doi: 10.1002/sdr.1715.
   Web of Science ®Google Scholar
• Wilson N, Mansoor OD, Boyd MJ, et al. We should not dismiss the possibility of eradicating COVID-19: comparisons with smallpox and polio. BMJ Glob Health. 2021;6(8):e006810. doi: 10.1136/bmjgh-2021-006810.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Tracking SARS-CoV-2 variants [Internet]. 2023 [cited 2023 Nov 8]. Available from: https://www.who.int/activities/tracking-SARS-CoV-2-variants/.
   Google Scholar
• Centers for Disease Control and Prevention. COVID data tracker - variant proportions [Internet]. Atlanta, GA: U.S. Department of Health and Human Services, CDC. 2023 [cited 2023 Nov 8]. Available from: https://covid.cdc.gov/covid-data-tracker/#variant-proportions.
   Google Scholar
• Duclos P. National Immunization Technical Advisory Groups (NITAGs): guidance for their establishment and strengthening. Vaccine. 2010;28 Suppl 1: a18–25. doi: 10.1016/j.vaccine.2010.02.027.
   PubMed Web of Science ®Google Scholar
• Drummond MF, Schwartz JS, Jönsson B, et al. Key principles for the improved conduct of health technology assessments for resource allocation decisions. Int J Technol Assess Health Care. 2008;24(03):244–258. doi: 10.1017/S0266462308081063.
   PubMedGoogle Scholar
• Neumann E by PJ, Sanders GD, Russell LB, editors, et al. Recommendations on perspectives for the reference case. Cost-effectiveness in health and medicine. 2nd ed. New to this Edition. Oxford; New York: Oxford University Press; 2016.
   Google Scholar
• Sharma D, Aggarwal AK, Downey LE, et al. National healthcare economic evaluation guidelines: a cross-country comparison. Pharmacoecon Open. 2021;5(3):349–364. doi: 10.1007/s41669-020-00250-7.
   PubMed Web of Science ®Google Scholar
• Kim DD, Silver MC, Kunst N, et al. Perspective and costing in cost-effectiveness analysis, 1974–2018. PharmacoEconomics. 2020;38(10):1135–1145. doi: 10.1007/s40273-020-00942-2.
   PubMed Web of Science ®Google Scholar
• Brouwer WBF, Culyer AJ, van Exel NJA, et al. Welfarism vs. extra-welfarism. J Health Econ. 2008;27(2):325–338. doi: 10.1016/j.jhealeco.2007.07.003.
   PubMed Web of Science ®Google Scholar
• Claxton K, Sculpher M, Culyer A. Mark versus Luke? Appropriate methods for the evaluation of public health interventions. Working Paper. CHE Research Paper. York, UK: Centre for Health Economics, University of York; 2007.
   Google Scholar
• Bloom DE, Fan VY, Sevilla JP. The broad socioeconomic benefits of vaccination. Sci Transl Med. 2018;10(441):eaaj2345. doi: 10.1126/scitranslmed.aaj2345.
   PubMed Web of Science ®Google Scholar
• Beck E, Biundo E, Devlin N, et al. Capturing the value of vaccination within health technology assessment and health economics: literature review and novel conceptual framework. Vaccine. 2022;40(30):4008–4016. doi: 10.1016/j.vaccine.2022.04.050.
   PubMed Web of Science ®Google Scholar
• Drummond M, Sculpher M, Claxton K, et al. Methods for the economic evaluation of health care programmes. 4th ed. Oxford, New York: Oxford University Press; 2015.
   Google Scholar
• Adler MD. Measuring social welfare: an introduction. New York: Oxford University Press; 2019 [cited 2022 Apr 29]. Available from: https://journals.openedition.org/oeconomia/11299.
   Google Scholar
• Kaplow L, Shavell S. Fairness versus welfare. Cambridge, MA: Harvard University Press; 2002.
   Google Scholar
• Fleurbaey M, Luchini S, Muller C, et al. Equivalent income and fair evaluation of health care. Health Econ. 2013;22(6):711–729. doi: 10.1002/hec.2859.
   PubMed Web of Science ®Google Scholar
• Stevenson B, Wolfers J. Economic growth and subjective well-being: reassessing the Easterlin Paradox [Internet]. 2008 [cited 2023 Sep 20]. Available from: https://www.brookings.edu/wp-content/uploads/2008/03/2008a_bpea_stevenson.pdf.
   Google Scholar
• Robinson LA, Hammitt JK, Jamison DT, et al. Conducting benefit-cost analysis in low- and middle-income countries: introduction to the special issue. J Benefit Cost Anal. 2019;10(Suppl 1):1–14. doi: 10.1017/bca.2019.4.
   PubMedGoogle Scholar
• The Joint Committee on Vaccination and Immunisation. Joint Committee on Vaccination and Immunisation [Internet]. GOV.UK. 2023 [cited 2023 Sep 19]. Available from: https://www.gov.uk/government/groups/joint-committee-on-vaccination-and-immunisation.
   Google Scholar
• The Joint Committee on Vaccination and Immunisation. JOINT COMMITTEE ON VACCINATION AND IMMUNISATION Code of Practice June 2013 [Internet]. 2013 [cited 2023 Sep 19]. Available from: https://assets.publishing.service.gov.uk/media/5a7b9b3440f0b62826a04a80/JCVI_Code_of_Practice_revision_2013_-_final.pdf.
   Google Scholar
• The Joint Committee on Vaccination and Immunisation. JCVI statement on COVID-19 vaccination of children aged 12 to 15 years: 3 September 2021 [Internet]. 2021 [cited 2023 Sep 19]. Available from: https://www.gov.uk/government/publications/jcvi-statement-september-2021-covid-19-vaccination-of-children-aged-12-to-15-years/jcvi-statement-on-covid-19-vaccination-of-children-aged-12-to-15-years-3-september-2021.
   Google Scholar
• Iacobucci G. Covid-19: Children aged 12-15 should be offered vaccine, say UK’s chief medical officers. BMJ. 2021;374:n2248. doi: 10.1136/bmj.n2248.
   PubMedGoogle Scholar
• Department of Health and Social Care. Young people aged 12 to 15 to be offered a COVID-19 vaccine [Internet]. GOV.UK. 2021 [cited 2023 Sep 19]. Available from: https://www.gov.uk/government/news/young-people-aged-12-to-15-to-be-offered-a-covid-19-vaccine.
   Google Scholar
• Huber C, Finelli L, Stevens W. The economic and social burden of the 2014 Ebola outbreak in West Africa. J Infect Dis. 2018;218(suppl_5):S698–S704. doi: 10.1093/infdis/jiy213.
   PubMed Web of Science ®Google Scholar
• Yang J, Vaghela S, Yarnoff B, et al. Estimated global public health and economic impact of COVID-19 vaccines in the pre-omicron era using real-world empirical data. Expert Rev Vaccines. 2023;22(1):54–65. doi: 10.1080/14760584.2023.2157817.
   PubMed Web of Science ®Google Scholar
• Connolly MP, Topachevskyi O, Standaert B, et al. The impact of rotavirus vaccination on discounted net tax revenue in Egypt. PharmacoEconomics. 2012;30(8):681–695. doi: 10.2165/11597750-000000000-00000.
   PubMed Web of Science ®Google Scholar
• Magesh S, John D, Li WT, et al. Disparities in COVID-19 outcomes by race, ethnicity, and socioeconomic status: a systematic review and meta-analysis. JAMA Netw Open. 2021;4(11):e2134147–e2134147. doi: 10.1001/jamanetworkopen.2021.34147.
   PubMed Web of Science ®Google Scholar
• Wasfy JH, Hidrue MK, Rockett H, et al. Socioeconomic and demographic characteristics of both inpatients and outpatients with positive testing for SARS-CoV-2. J Gen Intern Med. 2021;36(8):2522–2524. doi: 10.1007/s11606-021-06919-x.
   PubMed Web of Science ®Google Scholar
• Tan AX, Hinman JA, Abdel Magid HS, et al. Association between income inequality and county-level COVID-19 cases and deaths in the US. JAMA Netw Open. 2021;4(5):e218799–e218799. doi: 10.1001/jamanetworkopen.2021.8799.
   PubMed Web of Science ®Google Scholar
• Kochhar R, Bennett JU. labor market inches back from the COVID-19 shock, but recovery is far from complete [Internet]. Pew Research Center. 2021 [cited 2023 Sep 25]. Available from: https://www.pewresearch.org/short-reads/2021/04/14/u-s-labor-market-inches-back-from-the-covid-19-shock-but-recovery-is-far-from-complete/.
   Google Scholar
• Piacentini J, Frazis H, Meyer PB, et al. The Impact of COVID-19 on Labor Markets and Inequality [Internet]. BLS WORKING PAPERS. 2022 [cited 2023 Sep 25]. Available from: https://www.bls.gov/osmr/research-papers/2022/pdf/ec220060.pdf.
   Google Scholar
• Duroseau B, Kipshidze N, Limaye RJ. The impact of delayed access to COVID-19 vaccines in low- and lower-Middle-income countries. Front Public Health. 2022;10:1087138. Available from: . doi: 10.3389/fpubh.2022.1087138.
   PubMed Web of Science ®Google Scholar